- Conditions
- Advanced Malignant Solid Neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, +81 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
Clinical trial condition
Refractory Ependymoma
Explore clinical trials studying Refractory Ependymoma. Study availability and eligibility vary by location and protocol.
10 public trials
0 recruiting studies
Refractory Ependymoma trial results
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, +85 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States
Active, Not Recruiting
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
NCT02359565
- Conditions
- Brain Diseases, Brain Neoplasms, Brain Stem Neoplasms, +46 more
- Locations
-
- Children's Hospital Los Angeles Los Angeles, California, United States
- Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
- Children's Hospital Colorado Aurora, Colorado, United States
- Children's National Medical Center Washington D.C., District of Columbia, United States
Active, Not Recruiting
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04284774
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine Gland Neoplasms, Endocrine System Diseases, +102 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
Active, Not Recruiting
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213652
- Conditions
- Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +82 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States
Active, Not Recruiting
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, Female Urogenital Diseases, +80 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
Active, Not Recruiting
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
NCT03213704
- Conditions
- Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +83 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States
Active, Not Recruiting
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT03698994
- Conditions
- Advanced Malignant Solid Neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, +83 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States
Active, Not Recruiting
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, Female Urogenital Diseases, +85 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
Active, Not Recruiting
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
NCT03210714
- Conditions
- Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +74 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States